NICE Final Guidance On Blood Cancer Drug Jakavi™ (ruxolitinib) Delivers Major Setback For Myelofibrosis Patients

The only therapy available for a disease with a clear unmet medical need will not be made available to UK patients Novartis today expressed disappointment at the National Institute for Health and Clinical Excellence's (NICE) decision to publish final guidance not recommending ruxolitinib (INC424, Jakavi™) for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis[i]...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Lymphology/Lymphedema Source Type: news